drugset / Trial / NCT00731029

Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03

NCT00731029 ↗

Phase 3 Completed 239 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

This is a comparative vaccination study of the reactogenicity and immunogenicity of a thiomersal-free formulation of Influsplit SSW® 2002/2003 versus the standard formulation of Influsplit SSW® 2002/2003 in individuals over 18 years.

Timeline

Start
2002-09
Primary completion
2003-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Comparator Influsplit SSW®/Fluarix™ 2002/2003 Unknown — Intramuscular
Subject Thiomersal free trivalent influenza split vaccine 2002/2003 Unknown — Intramuscular

Indications